Third Quarter 2025
Third quarter 2025 results were reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation was followed by a Q&A session.
Featuring
Paul Hudson
Chief Executive Officer
François Roger
Chief Financial Officer
Houman Ashrafian
Head of Research and Development
Highlights
The growth momentum we saw in Q3 confirms continued sales and earnings progress and positions us well to achieve our full-year guidance. Our pipeline delivered important milestones for patients this quarter, including the approval of new and differentiated medicines, in the US for the rare disease immune thrombocytopenia and in China to delay onset of stage 3, type 1 diabetes.
Paul Hudson
Chief Executive Officer